New data for Roche’s OCREVUS (ocrelizumab) show benefit in disability progression and cognitive decline in both secondary progressive and primary progressive multiple sclerosis April 4, 2022April 23, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: Roche to present new OCREVUS (ocrelizumab) data in…Early treatment with Roche's OCREVUS leads to…[Ad hoc announcement pursuant to Art. 53 LR] Roche…Roche's Kadcyla is the first targeted therapy…Integrating Fluoroscopy Room and Radiography Room…World’s Only Instrument Capable of Performing Both…
